Home/ Stocks/ GOVX

GeoVax Labs, Inc. New

GOVX XNAS

$1.54 +0.01 (+0.40%) ▲ 15-min delayed

Open

$1.50

High

$1.54

Low

$1.45

Volume

29.1K

Market Cap

$3.34M

About GeoVax Labs, Inc. New

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-6,318,914	$-0.31
Q2 2025	$852.3K	$-5,369,783	$-0.35
Q1 2025	$1.64M	$-5,357,651	$-0.45
FY 2024	$3.95M	$-24,992,296	$-4.82

Related Market News

No specific coverage for GOVX yet. Check out our latest market news or earnings calendar.

Get GOVX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GeoVax Labs, Inc. New.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.